$27.68
Value $813M
HSTM and NVDA stock compared: price, dividend, valuation and results, from SEC filings.
$27.68
Value $813M
$156.14
Value $3.79T
HealthStream (HSTM) has a market value of $813M and NVIDIA (NVDA) $3.79T. Over the last year, with dividends, HSTM moved +13.9% and NVDA -17.7%. The P/E is 39.7 for HSTM and 19.7 for NVDA. Dividend yield: HSTM 0.49%, NVDA 0.33%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
HSTM$813M
NVDA$3.79T
NVDA is 4,669 times HSTM
Revenue, 12 months
HSTM$328M
NVDA$303B
NVDA is 924 times HSTM
Net income, 12 months
HSTM$20M
NVDA$193B
NVDA is 9,415 times HSTM
Operating margin
HSTM7.6%
NVDA65.2%
57.6 points apart
ROIC
HSTM5.3%
NVDA95.6%
90.3 points apart
P/E
HSTM39.7
NVDA19.7
HSTM is 2.0 times NVDA
Dividend yield
HSTM0.5%
NVDA0.3%
0.2 points apart
5-year return
HSTM+8.3%
NVDA+422.4%
414.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
HSTM+8.3%
NVDA+422.4%
| Period | HSTMWith dividends | NVDAWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +13.9%Price +13.1% | -17.7%Price -17.9% |
| 3 years since November 16, 2023 | +11.1%+3.6% a yearPrice +9.5% | +216.5%+46.8% a yearPrice +215.6% |
| 5 years since November 15, 2021 | +8.3%+1.6% a yearPrice +6.3% | +422.4%+39.2% a yearPrice +420.1% |
| 10 years since November 16, 2016 | +16.7%+1.6% a yearPrice +10.0% | +6,847.8%+52.8% a yearPrice +6,718.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
HSTMHealthStreamNVDANVIDIA
| Price | $27.68 | $156.14 |
|---|---|---|
| Market value | $813M | $3.79T |
| Enterprise value (EV) | $697M | $3.77T |
| P/E | 39.7 | 19.7 |
| P/E, 5-year median | 51.1 | 49.9 |
| P/B | 2.0 | 16.6 |
| EV/EBIT | 28.1 | 19.1 |
| Free cash flow yield | 8.5% | 3.4% |
| Revenue, 12 months | $328M | $303B |
|---|---|---|
| Net income, 12 months | $20M | $193B |
| Free cash flow, 12 months | $69M | $127B |
| Earnings per share, 12 months | $0.70 | $7.91 |
| Revenue growth, year on year | 4.3% | 65.5% |
| Revenue growth a year, past | +4.4%over 5 years | +66.9%over 5 years |
| EPS growth a year, past | +6.8%over 5 years | +95.2%over 5 years |
| Gross margin | 64.7% | 74.7% |
|---|---|---|
| Operating margin | 7.6% | 65.2% |
| Net margin | 6.3% | 63.7% |
| ROIC | 5.3% | 95.6% |
| ROE | 5.7% | 120.4% |
| Cash | $115M | $56.6B |
|---|---|---|
| Total debt | $13M | $38.9B |
| Net debt / EBITDA | -1.7 | -0.1 |
| Interest cover | – | 426.7× |
| Dividend yield | 0.5% | 0.3% |
|---|---|---|
| Dividend per share, 12 months | $0.14 | $0.52 |
| Dividend growth a year, past | – | +20.1%over 5 years |
| Buyback yield | 3.7% | 1.1% |
| Shareholder yield | 4.2% | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, NVIDIA ($3.79T) is about 4,669.3 times HealthStream ($813M), at today's prices.
Since November 16, 2016, HSTM's price moved +10.0% and NVDA's +6,718.3%. With dividends: HSTM +16.7% (+1.6% a year), NVDA +6,847.8% (+52.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.49% for HealthStream and 0.33% for NVIDIA. Over the last twelve months they paid $0.14 and $0.52 per share.
At today's price, the P/E is 39.7 for HSTM and 19.7 for NVDA. The median of the last five years was 51.1 and 49.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 6.3% for HealthStream and 63.7% for NVIDIA, and the operating margin 7.6% and 65.2%. Revenue was $328M and $303B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.